ADC Therapeutics SA has filed an updated Schedule 13G/A with the SEC, detailing changes in beneficial ownership. The filing, made on November 13, 2026, indicates that Prosight Management, LP and its affiliates now control a total of 399,900 shares of the company, which accounts for approximately 0.31% of ADC Therapeutics' outstanding shares. This update is significant as it reflects the ongoing evolution of ownership stakes within the pharmaceutical preparations sector.

Background

ADC Therapeutics SA is a company focused on developing and commercializing innovative therapies for patients with hematologic malignancies and solid tumors. The company operates within the SIC code 2834, which pertains to Pharmaceutical Preparations. ADC Therapeutics is publicly traded on the New York Stock Exchange under the ticker symbol ADCT. Recent filings include a Schedule 13G/A on November 13, 2026, and a 10-Q on November 9, 2026.

What the Filing Says

The Schedule 13G/A filing reveals that the reporting persons, which include Prosight Management, LP, Prosight Fund, LP, and other affiliates, have beneficially owned 399,900 shares of ADC Therapeutics. The filing states, "The figure in Item 11 is based upon 127,667,695 common shares of the issuer outstanding as of August 3rd, 2026, as disclosed in the Issuer's Form 10-Q, filed with the SEC on August 13th, 2026." This indicates a strategic interest in the company by these investment entities.

Impact

This update is likely to impact various stakeholders, including existing shareholders, potential investors, and market analysts. The ownership stake held by Prosight Management and its affiliates may influence the company's governance and strategic direction. Additionally, the filing highlights the competitive landscape within the pharmaceutical preparations industry, where investor sentiment can significantly affect stock performance and corporate strategies.

What's Next

The filing does not specify what happens next regarding the ownership changes or any potential actions from ADC Therapeutics or its investors. Stakeholders will likely monitor future filings for further developments.